The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials

被引:0
作者
Haili Qian
Feng Gao
Haijuan Wang
Fei Ma
机构
[1] Cancer Institute/Hospital,State Key Laboratory of Molecular Oncology
[2] Peking Union Medical College & Chinese Academy of Medical Sciences,Department of Medical Oncology
[3] Cancer Institute/Hospital,Health Division of Guard Bureau
[4] Peking Union Medical College & Chinese Academy of Medical Sciences,undefined
[5] General Staff Department of Chinese PLA,undefined
来源
BMC Cancer | / 14卷
关键词
Meta-analysis; Crizotinib; Anaplastic lymphoma kinase (ALK); Non-small cell lung cancer (NSCLC);
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 253 条
[1]  
Weinmann M(2003)Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer Lung Cancer 39 233-253
[2]  
Jeremic B(2013)Clinical use of crizotinib for the treatment of non-small cell lung cancer Biologics 7 91-101
[3]  
Toomes H(2011)Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2866-2874
[4]  
Friedel G(2001)Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results Lung Cancer 34 S95-S101
[5]  
Bamberg M(2012)Crizotinib for the treatment of patients with advanced non-small cell lung cancer Drugs Today (Barc) 48 271-282
[6]  
Roberts PJ(2014)Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer BMC Cancer 14 185-566
[7]  
Fukuoka M(2007)Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 561-1203
[8]  
Wu YL(2007)Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 1190-2402
[9]  
Thongprasert S(2014)ALK-positive non-small cell lung cancer: Mechanisms of resistance and emerging treatment options Cancer 120 2392-1046
[10]  
Sunpaweravong P(2013)Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation BMC Cancer 13 262-643